High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma
Background Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies with poor prognosis. There is no research about the clinical significance of serum soluble CD155 (sCD155) level for HCC. We aim to explore the prognostic and diagnostic value of sCD155 in HCC patients undergoing cura...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical laboratory analysis 2022-03, Vol.36 (3), p.e24259-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e24259 |
| container_title | Journal of clinical laboratory analysis |
| container_volume | 36 |
| creator | Jin, An‐Li Yang, Yi‐Hui Su, Xi Yang, Wen‐Jing Liu, Te Chen, Wei Li, Tong Ding, Lin Wang, Hao Wang, Bei‐Li Pan, Bai‐Shen Zhou, Jian Fan, Jia Yang, Xin‐Rong Guo, Wei |
| description | Background
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies with poor prognosis. There is no research about the clinical significance of serum soluble CD155 (sCD155) level for HCC. We aim to explore the prognostic and diagnostic value of sCD155 in HCC patients undergoing curative resection.
Methods
Serum sCD155 level in HCC patients was determined by enzyme‐linked immunosorbent assay. The prognostic significance of sCD155 was evaluated by Cox regression and Kaplan–Meier analyses. CD155 expression and biomarkers of immune cells in HCC tissues were detected by immunohistochemistry staining. The diagnostic significance of sCD155 was evaluated using receiver operating characteristic curve.
Results
Serum sCD155 level was significantly increased in HCC patients and predicted poor prognosis. The prognostic value of sCD155 remained in low recurrent risk subgroups of HCC. Serum sCD155 level was positively related to CD155 expression in HCC tissues. High serum sCD155 level was associated with decreased numbers of CD8+T cells and CD56+NK cells and increased number of CD163+M2 macrophages. Serum sCD155 level had better performance in distinguishing HCC patients from healthy donors and patients with chronic liver conditions than α‐fetoprotein. Among patients with α‐fetoprotein ≤ 20 ng/ml, serum sCD155 level could differentiate HCC patients from non‐HCC patients.
Conclusion
Serum sCD155 level represents a promising biomarker for diagnosis and prognosis of HCC. High serum sCD155 level may reflect an immunosuppressive tumor microenvironment in HCC.
Serum sCD155 level is elevated in HCC patients. High serum sCD155 level predicts poor prognosis and reflects an immunosuppressive tumor microenvironment in HCC. |
| doi_str_mv | 10.1002/jcla.24259 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8906055</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2637281606</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4489-ebffd507291ac380b2a585b0588724645c0b123ccbb5b5520f8478a4903340cf3</originalsourceid><addsrcrecordid>eNp9kc1uEzEUhS0EomlhwwMgS2wQ0pRrezzxbJCqQCkoEhtYWx7Hkzjyz2CPU_U1eGIcUipgwcp_3z06xwehFwQuCQB9u9dOXdKW8v4RWhDoRUMF5Y_RAoRYNgIIO0PnOe8BQPSke4rOGK-7jpAF-nFjtzucTSoe5-jK4AxevSecY2cOxuEpmY3Vc8ZTjKme4jbEbDNWYYN1TMk4NZuMb-28q3fYel8qUKY6l7M9GDwXXwe91SmacLApBm_CjG3AOzOpOWrjXHEqYa2StiF69Qw9GZXL5vn9eoG-XX_4urpp1l8-flpdrRvdtqJvzDCOGw5L2hOlmYCBKi74ALyGpm3Xcg0DoUzrYeAD5xRG0S6FantgrAU9sgv07qQ7lcGbja62knJyStardCejsvLvl2B3chsPUvTQAedV4PW9QIrfi8mz9DYf86hgYsmSdpRVlvC2oq_-QfexpFDjVYotqSAddJV6c6LqZ-WczPhghoA8Vi2PVctfVVf45Z_2H9Df3VaAnIBb68zdf6Tk59X66iT6ExyFt5w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2637281606</pqid></control><display><type>article</type><title>High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Jin, An‐Li ; Yang, Yi‐Hui ; Su, Xi ; Yang, Wen‐Jing ; Liu, Te ; Chen, Wei ; Li, Tong ; Ding, Lin ; Wang, Hao ; Wang, Bei‐Li ; Pan, Bai‐Shen ; Zhou, Jian ; Fan, Jia ; Yang, Xin‐Rong ; Guo, Wei</creator><creatorcontrib>Jin, An‐Li ; Yang, Yi‐Hui ; Su, Xi ; Yang, Wen‐Jing ; Liu, Te ; Chen, Wei ; Li, Tong ; Ding, Lin ; Wang, Hao ; Wang, Bei‐Li ; Pan, Bai‐Shen ; Zhou, Jian ; Fan, Jia ; Yang, Xin‐Rong ; Guo, Wei</creatorcontrib><description>Background
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies with poor prognosis. There is no research about the clinical significance of serum soluble CD155 (sCD155) level for HCC. We aim to explore the prognostic and diagnostic value of sCD155 in HCC patients undergoing curative resection.
Methods
Serum sCD155 level in HCC patients was determined by enzyme‐linked immunosorbent assay. The prognostic significance of sCD155 was evaluated by Cox regression and Kaplan–Meier analyses. CD155 expression and biomarkers of immune cells in HCC tissues were detected by immunohistochemistry staining. The diagnostic significance of sCD155 was evaluated using receiver operating characteristic curve.
Results
Serum sCD155 level was significantly increased in HCC patients and predicted poor prognosis. The prognostic value of sCD155 remained in low recurrent risk subgroups of HCC. Serum sCD155 level was positively related to CD155 expression in HCC tissues. High serum sCD155 level was associated with decreased numbers of CD8+T cells and CD56+NK cells and increased number of CD163+M2 macrophages. Serum sCD155 level had better performance in distinguishing HCC patients from healthy donors and patients with chronic liver conditions than α‐fetoprotein. Among patients with α‐fetoprotein ≤ 20 ng/ml, serum sCD155 level could differentiate HCC patients from non‐HCC patients.
Conclusion
Serum sCD155 level represents a promising biomarker for diagnosis and prognosis of HCC. High serum sCD155 level may reflect an immunosuppressive tumor microenvironment in HCC.
Serum sCD155 level is elevated in HCC patients. High serum sCD155 level predicts poor prognosis and reflects an immunosuppressive tumor microenvironment in HCC.</description><identifier>ISSN: 0887-8013</identifier><identifier>EISSN: 1098-2825</identifier><identifier>DOI: 10.1002/jcla.24259</identifier><identifier>PMID: 35089611</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>biomarker ; Biomarkers ; Biomarkers, Tumor ; Carcinoma, Hepatocellular - pathology ; CD163 antigen ; CD56 antigen ; CD8 antigen ; CD8-Positive T-Lymphocytes - pathology ; Cholangiocarcinoma ; diagnosis ; Hepatitis ; Hepatocellular carcinoma ; Humans ; Immunohistochemistry ; immunosuppression ; Laboratories ; Liver cancer ; Liver Neoplasms - pathology ; Lymphocytes T ; Macrophages ; Medical prognosis ; Metastasis ; Patients ; Prognosis ; Risk groups ; soluble poliovirus receptor ; Standard deviation ; Statistical analysis ; Surgery ; Tumor Microenvironment ; Tumors</subject><ispartof>Journal of clinical laboratory analysis, 2022-03, Vol.36 (3), p.e24259-n/a</ispartof><rights>2022 The Authors. published by Wiley Periodicals LLC</rights><rights>2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.</rights><rights>2022. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4489-ebffd507291ac380b2a585b0588724645c0b123ccbb5b5520f8478a4903340cf3</citedby><cites>FETCH-LOGICAL-c4489-ebffd507291ac380b2a585b0588724645c0b123ccbb5b5520f8478a4903340cf3</cites><orcidid>0000-0003-4406-1094 ; 0000-0001-5167-170X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906055/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906055/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35089611$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jin, An‐Li</creatorcontrib><creatorcontrib>Yang, Yi‐Hui</creatorcontrib><creatorcontrib>Su, Xi</creatorcontrib><creatorcontrib>Yang, Wen‐Jing</creatorcontrib><creatorcontrib>Liu, Te</creatorcontrib><creatorcontrib>Chen, Wei</creatorcontrib><creatorcontrib>Li, Tong</creatorcontrib><creatorcontrib>Ding, Lin</creatorcontrib><creatorcontrib>Wang, Hao</creatorcontrib><creatorcontrib>Wang, Bei‐Li</creatorcontrib><creatorcontrib>Pan, Bai‐Shen</creatorcontrib><creatorcontrib>Zhou, Jian</creatorcontrib><creatorcontrib>Fan, Jia</creatorcontrib><creatorcontrib>Yang, Xin‐Rong</creatorcontrib><creatorcontrib>Guo, Wei</creatorcontrib><title>High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma</title><title>Journal of clinical laboratory analysis</title><addtitle>J Clin Lab Anal</addtitle><description>Background
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies with poor prognosis. There is no research about the clinical significance of serum soluble CD155 (sCD155) level for HCC. We aim to explore the prognostic and diagnostic value of sCD155 in HCC patients undergoing curative resection.
Methods
Serum sCD155 level in HCC patients was determined by enzyme‐linked immunosorbent assay. The prognostic significance of sCD155 was evaluated by Cox regression and Kaplan–Meier analyses. CD155 expression and biomarkers of immune cells in HCC tissues were detected by immunohistochemistry staining. The diagnostic significance of sCD155 was evaluated using receiver operating characteristic curve.
Results
Serum sCD155 level was significantly increased in HCC patients and predicted poor prognosis. The prognostic value of sCD155 remained in low recurrent risk subgroups of HCC. Serum sCD155 level was positively related to CD155 expression in HCC tissues. High serum sCD155 level was associated with decreased numbers of CD8+T cells and CD56+NK cells and increased number of CD163+M2 macrophages. Serum sCD155 level had better performance in distinguishing HCC patients from healthy donors and patients with chronic liver conditions than α‐fetoprotein. Among patients with α‐fetoprotein ≤ 20 ng/ml, serum sCD155 level could differentiate HCC patients from non‐HCC patients.
Conclusion
Serum sCD155 level represents a promising biomarker for diagnosis and prognosis of HCC. High serum sCD155 level may reflect an immunosuppressive tumor microenvironment in HCC.
Serum sCD155 level is elevated in HCC patients. High serum sCD155 level predicts poor prognosis and reflects an immunosuppressive tumor microenvironment in HCC.</description><subject>biomarker</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>CD163 antigen</subject><subject>CD56 antigen</subject><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes - pathology</subject><subject>Cholangiocarcinoma</subject><subject>diagnosis</subject><subject>Hepatitis</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>immunosuppression</subject><subject>Laboratories</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - pathology</subject><subject>Lymphocytes T</subject><subject>Macrophages</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Risk groups</subject><subject>soluble poliovirus receptor</subject><subject>Standard deviation</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Tumor Microenvironment</subject><subject>Tumors</subject><issn>0887-8013</issn><issn>1098-2825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc1uEzEUhS0EomlhwwMgS2wQ0pRrezzxbJCqQCkoEhtYWx7Hkzjyz2CPU_U1eGIcUipgwcp_3z06xwehFwQuCQB9u9dOXdKW8v4RWhDoRUMF5Y_RAoRYNgIIO0PnOe8BQPSke4rOGK-7jpAF-nFjtzucTSoe5-jK4AxevSecY2cOxuEpmY3Vc8ZTjKme4jbEbDNWYYN1TMk4NZuMb-28q3fYel8qUKY6l7M9GDwXXwe91SmacLApBm_CjG3AOzOpOWrjXHEqYa2StiF69Qw9GZXL5vn9eoG-XX_4urpp1l8-flpdrRvdtqJvzDCOGw5L2hOlmYCBKi74ALyGpm3Xcg0DoUzrYeAD5xRG0S6FantgrAU9sgv07qQ7lcGbja62knJyStardCejsvLvl2B3chsPUvTQAedV4PW9QIrfi8mz9DYf86hgYsmSdpRVlvC2oq_-QfexpFDjVYotqSAddJV6c6LqZ-WczPhghoA8Vi2PVctfVVf45Z_2H9Df3VaAnIBb68zdf6Tk59X66iT6ExyFt5w</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Jin, An‐Li</creator><creator>Yang, Yi‐Hui</creator><creator>Su, Xi</creator><creator>Yang, Wen‐Jing</creator><creator>Liu, Te</creator><creator>Chen, Wei</creator><creator>Li, Tong</creator><creator>Ding, Lin</creator><creator>Wang, Hao</creator><creator>Wang, Bei‐Li</creator><creator>Pan, Bai‐Shen</creator><creator>Zhou, Jian</creator><creator>Fan, Jia</creator><creator>Yang, Xin‐Rong</creator><creator>Guo, Wei</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4406-1094</orcidid><orcidid>https://orcid.org/0000-0001-5167-170X</orcidid></search><sort><creationdate>202203</creationdate><title>High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma</title><author>Jin, An‐Li ; Yang, Yi‐Hui ; Su, Xi ; Yang, Wen‐Jing ; Liu, Te ; Chen, Wei ; Li, Tong ; Ding, Lin ; Wang, Hao ; Wang, Bei‐Li ; Pan, Bai‐Shen ; Zhou, Jian ; Fan, Jia ; Yang, Xin‐Rong ; Guo, Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4489-ebffd507291ac380b2a585b0588724645c0b123ccbb5b5520f8478a4903340cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>biomarker</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>CD163 antigen</topic><topic>CD56 antigen</topic><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes - pathology</topic><topic>Cholangiocarcinoma</topic><topic>diagnosis</topic><topic>Hepatitis</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>immunosuppression</topic><topic>Laboratories</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - pathology</topic><topic>Lymphocytes T</topic><topic>Macrophages</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Risk groups</topic><topic>soluble poliovirus receptor</topic><topic>Standard deviation</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Tumor Microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jin, An‐Li</creatorcontrib><creatorcontrib>Yang, Yi‐Hui</creatorcontrib><creatorcontrib>Su, Xi</creatorcontrib><creatorcontrib>Yang, Wen‐Jing</creatorcontrib><creatorcontrib>Liu, Te</creatorcontrib><creatorcontrib>Chen, Wei</creatorcontrib><creatorcontrib>Li, Tong</creatorcontrib><creatorcontrib>Ding, Lin</creatorcontrib><creatorcontrib>Wang, Hao</creatorcontrib><creatorcontrib>Wang, Bei‐Li</creatorcontrib><creatorcontrib>Pan, Bai‐Shen</creatorcontrib><creatorcontrib>Zhou, Jian</creatorcontrib><creatorcontrib>Fan, Jia</creatorcontrib><creatorcontrib>Yang, Xin‐Rong</creatorcontrib><creatorcontrib>Guo, Wei</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical laboratory analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jin, An‐Li</au><au>Yang, Yi‐Hui</au><au>Su, Xi</au><au>Yang, Wen‐Jing</au><au>Liu, Te</au><au>Chen, Wei</au><au>Li, Tong</au><au>Ding, Lin</au><au>Wang, Hao</au><au>Wang, Bei‐Li</au><au>Pan, Bai‐Shen</au><au>Zhou, Jian</au><au>Fan, Jia</au><au>Yang, Xin‐Rong</au><au>Guo, Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma</atitle><jtitle>Journal of clinical laboratory analysis</jtitle><addtitle>J Clin Lab Anal</addtitle><date>2022-03</date><risdate>2022</risdate><volume>36</volume><issue>3</issue><spage>e24259</spage><epage>n/a</epage><pages>e24259-n/a</pages><issn>0887-8013</issn><eissn>1098-2825</eissn><abstract>Background
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies with poor prognosis. There is no research about the clinical significance of serum soluble CD155 (sCD155) level for HCC. We aim to explore the prognostic and diagnostic value of sCD155 in HCC patients undergoing curative resection.
Methods
Serum sCD155 level in HCC patients was determined by enzyme‐linked immunosorbent assay. The prognostic significance of sCD155 was evaluated by Cox regression and Kaplan–Meier analyses. CD155 expression and biomarkers of immune cells in HCC tissues were detected by immunohistochemistry staining. The diagnostic significance of sCD155 was evaluated using receiver operating characteristic curve.
Results
Serum sCD155 level was significantly increased in HCC patients and predicted poor prognosis. The prognostic value of sCD155 remained in low recurrent risk subgroups of HCC. Serum sCD155 level was positively related to CD155 expression in HCC tissues. High serum sCD155 level was associated with decreased numbers of CD8+T cells and CD56+NK cells and increased number of CD163+M2 macrophages. Serum sCD155 level had better performance in distinguishing HCC patients from healthy donors and patients with chronic liver conditions than α‐fetoprotein. Among patients with α‐fetoprotein ≤ 20 ng/ml, serum sCD155 level could differentiate HCC patients from non‐HCC patients.
Conclusion
Serum sCD155 level represents a promising biomarker for diagnosis and prognosis of HCC. High serum sCD155 level may reflect an immunosuppressive tumor microenvironment in HCC.
Serum sCD155 level is elevated in HCC patients. High serum sCD155 level predicts poor prognosis and reflects an immunosuppressive tumor microenvironment in HCC.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>35089611</pmid><doi>10.1002/jcla.24259</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-4406-1094</orcidid><orcidid>https://orcid.org/0000-0001-5167-170X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-8013 |
| ispartof | Journal of clinical laboratory analysis, 2022-03, Vol.36 (3), p.e24259-n/a |
| issn | 0887-8013 1098-2825 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8906055 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | biomarker Biomarkers Biomarkers, Tumor Carcinoma, Hepatocellular - pathology CD163 antigen CD56 antigen CD8 antigen CD8-Positive T-Lymphocytes - pathology Cholangiocarcinoma diagnosis Hepatitis Hepatocellular carcinoma Humans Immunohistochemistry immunosuppression Laboratories Liver cancer Liver Neoplasms - pathology Lymphocytes T Macrophages Medical prognosis Metastasis Patients Prognosis Risk groups soluble poliovirus receptor Standard deviation Statistical analysis Surgery Tumor Microenvironment Tumors |
| title | High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T01%3A13%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20serum%20soluble%20CD155%20level%20predicts%20poor%20prognosis%20and%20correlates%20with%20an%20immunosuppressive%20tumor%20microenvironment%20in%20hepatocellular%20carcinoma&rft.jtitle=Journal%20of%20clinical%20laboratory%20analysis&rft.au=Jin,%20An%E2%80%90Li&rft.date=2022-03&rft.volume=36&rft.issue=3&rft.spage=e24259&rft.epage=n/a&rft.pages=e24259-n/a&rft.issn=0887-8013&rft.eissn=1098-2825&rft_id=info:doi/10.1002/jcla.24259&rft_dat=%3Cproquest_pubme%3E2637281606%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2637281606&rft_id=info:pmid/35089611&rfr_iscdi=true |